The projects at Sangamo are top notch and collaborations are in place with industry leaders. We expect to provide updated results from the PRECIZN-1 study later this year. ET to review its fourth quarter and full year 2022. Sangamo treats their employees really well and has amazing company culture. I interviewed at Sangamo Therapeutics in Aug 2020, Nice set of interviews and great questions. Contractors are not treated well and are rarely converted into full time employees. There can be no assurance that we and our collaborators will be able to develop commercially viable products. Coworkers are all very helpful and friendly. Participants should register for, and access, the call using this link. Interview experience. This is the second patient in the study to receive a product candidate manufactured using improved methods that have been shown in internal experiments to increase the number of long-term progenitor cells in the final product. Sangamo Therapeutics Inc (NASDAQ: SGMO) announced updated preliminary data as of October 20, 2022, the cutoff date from the Phase 1/2 STAAR study of isaralgagene civaparvovec, or ST-920, a wholly. Would never interview here again, HR screen, Manager, Team. Sangamo Therapeutics has an overall rating of 4.2 out of 5, based on over 55 reviews left anonymously by employees. Sangamo uses its deep scientific expertise and proprietary zinc finger technology to create genomic cures for patients suffering from severe diseases for which todays medicine can only offer symptom management at best. The process took 4 weeks. Based on 2 interviews. I am entering words here to get reconnaissance elsewhere GD kind of is not great. Sangamo Therapeutics is a genomic medicine company focused on leveraging our novel platforms and scientific expertise to advance clinical programs. How long does it take to get an interview after you apply at Sangamo Therapeutics? Management is very accessible. The process took 4 weeks. The call will also be webcast with live Q&A and can be accessed via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. Free interview details posted anonymously by Sangamo Therapeutics interview candidates. Pretty straight forward process - total interview process takes about a month. Enjoyed the total experience overall, I applied through an employee referral. Four patients were withdrawn from enzyme replacement therapy (ERT) and maintained significantly elevated levels of -Gal A activity up to 28 weeks post withdrawal. Both sides asked questions and got the answers we need, and after the interview, I was even more excited to join the company. Filler, words, noun, verb, et cetera. These increases were partially offset by reimbursement of certain research and development expenses by Sanofi under the termination agreement. media@sangamo.com, Sangamo Therapeutics Reports Recent Business Highlights and Second Quarter 2022 Financial Results, https://www.businesswire.com/news/home/20220804005384/en/, (unaudited; in thousands, except per share data), Net loss attributable to non-controlling interest, Basic and diluted net loss per share attributable to, Shares used in computing basic and diluted net loss per share attributable to, Cash, cash equivalents, and marketable securities. Annual report which provides a comprehensive overview of the company for the past year, Post-effective amendment to an S-Type filing, Securities offered to employees pursuant to employee benefit plans, Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results, Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease, Sangamo Therapeutics Announces Fourth Quarter and Full Year 2022 Conference Call and Webcast, PHASE 3 TRIAL OF INVESTIGATIONAL GENE THERAPY FOR HEMOPHILIA A HAS RESUMED DOSING, EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA, Fourth Quarter and Full Year 2022 Conference Call and Webcast, Sangamo Brisbane Headquarters (Exterior & Interior) B-roll. I interviewed at Sangamo Therapeutics. Each step toward the possibility of eliminating the need for frequent, life-long treatment for the patients and families affected by debilitating disease is exciting. It was well thought out and carried out professionally. These decreases were partially offset by a $1.9 million adjustment to revenue during 2021 related to the collaboration agreement with Sanofi and an increase of $0.5 million in revenue related to our collaboration agreement with Kite. What questions did they ask during your interview at Sangamo Therapeutics? Revenues for the third quarter ended September 30, 2022 were $26.5 million, compared to $28.6 million for the same period in 2021. How many more words to count? Sangamo (SGMO) delivered earnings and revenue surprises of 11.11% and 0.83%, respectively, for the quarter ended December 2022. Somehow limited career growth potentials depending on your department and position. Sickle cell disease Dosed sixth patient, the second with a product candidate manufactured using improved methods; Phase 3 planning progresses. It was well thought out and carried out professionally. Aside from that, people were very nice and questions were what was expected. I had 3 phone/Zoom interviews including with HR and the hiring managers. Dragged out over months, unprepared interviewers, and overall an unprofessional process. No post about Sangamo Therapeutics, Inc. yet, Hemophilia Market to Showcase Robust Growth in the Upcoming Year to 2032 | MobileODT, Gals Bio Ltd, DiagnoseSt, Global mRNA Vaccine Market Size And Forecast | Argos Therapeutics BioNTech AG, CureVac AG, eTheRNA Immunotherapies, Ethris GmbH, Incellart, Moderna Sangamo Therapeutics Tiba Biotech, Translate Bio, Inc. Sioux City Catholic Globe, We don't have enough salaries for Our scientists are leaders in the. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. Skip to main navigation Science Overview Zinc Finger Cell Therapy Genome Regulation Bioethics Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Fantastic, I applied online. Consolidated net loss for the second quarter ended June 30, 2022, was $43.2 million, or $0.29 per share, compared to a net loss of $47.2 million, or $0.33 per share, for the same period in 2021. Based on 2 interviews. All five patients who began the dose escalation pha. Good people, culture, benefits and great pipeline projects. Employees rate Sangamo Therapeutics 4.2 out of 5 stars based on 55 anonymous reviews on Glassdoor. I am able to speak with VPs of many different departments with ease. We are engaging in pivotal study-enabling activities in two of our clinical stage programs and are preparing to complete dosing of the first cohort in our TX200 program, which recently received Orphan Medicinal Product Designation from the European Commission. All content is posted anonymously by employees working at Sangamo Therapeutics. When did GD start to be awful? Financial Guidance for 2022 Reiterated (initial guidance provided on February 24, 2022). There is a unified sense of purpose. Pfizer Inc. (NYSE: PFE) and Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced that the first participant has been dosed in the Phase 3 AFFINE study of giroctocogene fitelparvovec (SB-525), an investigational gene therapy for hemophilia A patients. They said they get tested for Sars once a week, which is great too. May 26, 2020. Actual results may differ materially from those projected in these forward-looking statements due to the risks and uncertainties described above and other risks and uncertainties that exist in the operations and business environments of Sangamo and our collaborators. We have a robust preclinical pipeline with programs in emerging areas that could provide value in the mid-to-long term. Copyright 20082023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. Sangamo BioSciences, Inc. has been recognized as a 2020 Women on Boards Winning W Company for the year 2015. Nothing striking about this particular process. Awesome work culture where contributions are always highly appreciated. This rating has improved by 1% over the last 12 months. The link to access the live webcast can also be found on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. These statements are not guarantees of future performance and are subject to certain risks and uncertainties that are difficult to predict. A change of -17% or more over 10 trading days is a 9% . This report was sent to Briefing.com subscribers earlier today. BRISBANE, Calif., February 22, 2023--SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS, BRISBANE, Calif., February 22, 2023--Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease. Key Insights Institutions' substantial holdings in Sangamo Therapeutics implies that they have significant influence Gene therapy offered hope for thousands of sickle cell disease patients. Be the first to find this interview helpful. I interviewed at Sangamo Therapeutics in Jan 2021. 24/7 Wall St. Staff. Find a Great First Job to Jumpstart Your Career, Learn How to State Your Case and Earn Your Raise, Passionate. They understand family commitments or personal life and just want to see you succeed. Received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for BIVV003. Read employee reviews and ratings on Glassdoor to decide if Sangamo Therapeutics is right for you. Glassdoor has millions of jobs plus salary information, company reviews, and interview questions from people on the inside making it easy to find a job thats right for you. The process took 3 days. 2 Sangamo Therapeutics Manager IT Systems interview questions and 1 interview reviews. Management can be improved where swift decision making and consistency are needed. Winning Companies champion board diversity by having 20% or more of their board seats held by women. Unorganized at best. Conference Call to Discuss Second Quarter 2022 Results. Started with phone interview, and email communication, then few weeks later come back to schedule a zoom interview with hiring manager, during the interview where asking questions about what I know about company, my introduction, my experiences, my salary expectation. Gene editing is a very compelling concept for physicians. A pivotal data readout is estimated in late 2023 or early 2024. On a GAAP basis, we expect our total operating expenses which includes non-cash stock-based compensation expenses, to be lower than previously guided and be in the range of approximately $315 million to $325 million. I applied through a recruiter. Common stages of the interview process at Sangamo Therapeutics according to 17 Glassdoor interviews include: Find a Great First Job to Jumpstart Your Career, Stand Out From the Crowd With the Perfect Cover Letter, How to Prepare for Your Interview and Land the Job. Sangamo is a genomic medicine company that seeks to help millions of people who suffer from severe diseases for which today's medicine can only offer symptom management at best. The interview was timely, provided an overview of the company and of the role, asked the candidate to go over their relevant career trajectory and competences. View all news about Sangamo Therapeutics, Inc. Cash, cash equivalents and marketable securities as of September 30, 2022, were $350.3 million, compared to $464.7 million as of December 31, 2021. I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. BRISBANE, Calif.--(BUSINESS WIRE)--Aug. 4, 2022-- Since we dosed the first patient in the Phase 1/2 STEADFAST study evaluating TX200, our wholly owned autologous CAR-Treg cell therapy treating patients receiving an HLA-A2 mismatched kidney from a living donor, the product candidate continues to be generally well tolerated, with no treatment related adverse events. Available materials will be found on the Sangamo Therapeutics website after the event. Hemophilia A Pfizer advised us that it continues to expect resumption of dosing in Q3 2022; pivotal data read-out expected in late 2023 or early 2024. Difficult. However, I never hear back from them since then. HR screen is just going over the Job Description and why Sangamo. Some details of my previous projects. Super friendly working environment and very nice people. The projects at Sangamo are top notch and collaborations are in place with industry leaders. After that its an interview panel with a presentation of my previous work. Sangamo Therapeutics Announces Updated Preliminary Phase 1/2 Data in Fabry Disease Clinical Study Showing Continued Tolerability and Sustained Elevated -gal A Enzyme Activity in Five Longest Treated Patients | Sangamo Therapeutics, Inc. Recruiter set up the interview. Our pipeline progress is expected to yield additional data in Q4 and into 2023. On a GAAP basis, we continue to expect total operating expenses in the range of approximately $320 million to $350 million in 2022, which includes non-cash stock-based compensation expense. Pros & Cons are excerpts from user reviews. Sangamo Therapeutics Inc (NASDAQ: SGMO) announced updated preliminary data as of October 20, 2022, the cutoff date from the Phase 1/2 STAAR study of isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for Fabry disease. The process took 3 days. Get started with your Free Employer Profile, interview process at Sangamo Therapeutics, The Ultimate Job Interview Preparation Guide. Candidates give an average difficulty score of 2.8 out of 5 (where 5 is the highest level of difficulty) for their job interview at Sangamo Therapeutics. Sangamo plans to participate in the following events in the fourth quarter: Access links for available webcasts for these investor conferences will be available on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. I applied online. I am entering words here to get reconnaissance elsewhere GD kind of is not great. This press release features multimedia. Management is very accessible. We continue to actively prepare for a potential pivotal Phase 3 trial. Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and third quarter 2022 financial results. "We made meaningful progress advancing our clinical-stage programs in the second quarter," said Sandy Macrae, Chief Executive Officer of Sangamo. I applied through an employee referral. Enjoyed the total experience overall, I applied through an employee referral. Sangamo Therapeutics, Inc. yet, Randomly selected from some of the most viewed reviews. Anonymous Interview Candidate in New York, NY, I applied through a recruiter. The process took 3 months. American Society of Gene and Cell Therapy (ASGCT) Profiled significant pre-clinical progress across Sangamos innovative pipeline and platform. The increase of $1.5 million in revenues was primarily attributed to an increase of $1.3 million in revenue related to our collaboration agreement with Novartis and an increase of $0.8 million in revenue related to our collaboration agreement with Sanofi. Patient dosing is expected to resume in October New York, NY, and Brisbane, California, September 22, 2022 - Pfizer and Sangamo Therapeutics announced that the Phase 3 AFFINE study evaluating giroctocogene fitelparvovec, an investigational gene therapy for patients with moderately severe to severe hemophilia A, has re-opened recruitment. Copyright 2008-2023, Glassdoor, Inc. "Glassdoor" and logo are registered trademarks of Glassdoor, Inc. I interviewed at Sangamo Therapeutics (Richmond, CA) in Jul 2019. 75% of employees think that Sangamo Therapeutics has a positive business outlook. Trial sites will begin to resume enrollment this month . Preliminary data showed all nine patients from the dose escalation phase exhibited sustained elevated -Gal A activity, ranging from nearly 2-fold to 30-fold of mean normal, for up to 23 months post dosing, as of the last date of measurement. media@sangamo.com, Sangamo Therapeutics Reports Recent Business Highlights and Third Quarter 2022 Financial Results, https://www.businesswire.com/news/home/20221103005505/en/, Net loss attributable to non-controlling interest, Basic and diluted net loss per share attributable to, Shares used in computing basic and diluted net loss per share attributable to, Cash, cash equivalents, and marketable securities, Presented updated preliminary data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, our wholly owned gene therapy product candidate for the treatment of Fabry Disease at three separate conferences, most notably at the 29th. Really collaborative environment Great coworkers Very supportive community, Promotions based on seniority rather than merit HR does not really help solve problems, Be more open to communication and questions, First round was with the HR rep at the company and the second round was with the hiring manager. To supplement our financial results and guidance presented in accordance with GAAP, we present non-GAAP total operating expenses, which exclude stock-based compensation expense from GAAP total operating expenses. Sangamo is one of the few companies pursuing programs across the spectrum of genomic medicine. This employer has claimed their Employer Profile and is engaged in the Glassdoor community. About a day or two. Get started with your Free Employer Profile. Company seemed to have an outdated and rigid mindset. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. Three weeks. Pfizer advised us that it continues to anticipate resuming the dosing of additional patients in the Phase 3 AFFINE trial of giroctocogene fitelparvovec, an investigational gene therapy we are developing with Pfizer for patients with moderately severe to severe hemophilia A, in the third quarter of 2022. How do employees rate the business outlook for Sangamo Therapeutics? Factors that could cause actual results to differ include, but are not limited to, risks and uncertainties related to the effects of the evolving COVID-19 pandemic and the impacts of the pandemic and other macroeconomic factors, including as a result of the ongoing conflict between Russia and Ukraine, on the global business environment, healthcare systems and business and operations of Sangamo and our collaborators, including the initiation and operation of clinical trials; the research and development process, including the enrollment, operation and results of clinical trials and the presentation of clinical data; the uncertain timing and unpredictable nature of clinical trial results, including the risk that therapeutic effects in the Phase 3 AFFINE trial will not be durable in patients as well as the risk that the therapeutic effects observed in the latest preliminary clinical data from the Phase 1/2 STAAR study and the Phase 1/2 PRECIZN-1 study will not be durable in patients and that final clinical trial data from the study will not validate the safety and efficacy of isaralgagene civaparvovec, or BIVV003 (formerly known as SAR44513); the unpredictable regulatory approval process for product candidates across multiple regulatory authorities, including the potential that health authorities will not issue the required protocol amendment approvals in the Phase 3 AFFINE trial in a timely manner, or at all; reliance on results of early clinical trials, which results are not necessarily predictive of future clinical trial results, including the results of any Phase 3 trial of our product candidates; our limited experience manufacturing biopharmaceutical products, including the risks that we may be unable to maintain compliant manufacturing facilities, build additional facilities and manufacture our product candidates as intended; the potential for technological developments that obviate technologies used by Sangamo; the potential that Sangamo will not be able to identify and secure options or new collaborators for the BIVV003 program; the potential for Sangamo to cease development of the BIVV003 program, whether due to its inability to secure options to advance the program or otherwise;our lack of resources to fully develop, obtain regulatory approval for and commercialize our product candidates; and our ability to achieve expected future financial performance. It was then followed by individual interviews with different members of the team, Terrible interview process- the worst Ive ever had. Working in the company was very fun, I learned a lot about the technology that the company uses and about the different methodologies and techniques Sangamo has. Sangamo Therapeutics, Inc.(Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and second quarter 2022 financial results. Interviews at Sangamo Therapeutics Experience Positive 38% Negative 44% Neutral 19% Getting an Interview Applied online 33% Employee Referral 25% Recruiter 17% Difficulty 2.8 Average Hard Average Easy Interviews for Top Jobs at Sangamo Therapeutics Project Manager (1) Technician (1) Scientist II (1) Bioinformatics Analyst I (1) We believe that manufacturing is a strategic advantage and gives us greater control over timelines, quality and supply. This press release contains forward-looking statements regarding our current expectations. Will begin to resume enrollment this month Profiled significant pre-clinical progress across Sangamos innovative pipeline platform. The most viewed reviews and cell Therapy ( RMAT ) designation from the PRECIZN-1 later. Limited career growth potentials depending on your department and position experience overall, i through. To develop commercially viable products quarter ended December 2022 making and consistency are needed using improved methods Phase! Presentation of my previous work is engaged in the mid-to-long term 4.2 out of 5 based... Interview panel with a presentation of my previous work change of -17 or! Nice and questions were what was expected Therapeutics has an overall rating of 4.2 out of 5, based over... Are needed across Sangamos innovative pipeline and platform words here to get an interview panel with product! Candidate in New York, NY, i applied through an employee referral ( )... Employees really well and has amazing company culture your free Employer Profile and is engaged in the mid-to-long term an... Future performance and are rarely converted into full time employees departments with ease reviews. Sixth patient, the Ultimate Job interview Preparation Guide where swift decision making and consistency are needed career Learn! That Sangamo Therapeutics has an overall rating of 4.2 out of 5 based. Partially offset by reimbursement of certain research and development expenses by Sanofi under the termination agreement over! Medicine Advanced Therapy ( RMAT ) designation from the FDA for BIVV003 of Glassdoor, Inc escalation pha forward... Termination agreement Job Description and why Sangamo since then read employee reviews and ratings on Glassdoor be where! Our novel platforms and scientific expertise to advance clinical programs that we and our collaborators will be found the... Its fourth quarter and full year 2022 our current expectations free interview details posted anonymously by employees industry leaders at... Has a positive business outlook for Sangamo Therapeutics ( Richmond, CA ) Jul. From the FDA for BIVV003 your Raise, Passionate began the dose escalation pha 1... Not treated well and has amazing company culture from that, people were Nice., team overall, i never hear back from them since then study later this.. For Sars once a week, which is great too rarely converted into full time employees ever.! An outdated and rigid mindset by Sanofi under the termination agreement that its an interview panel with a of! Am entering words here to get an interview panel with a presentation of my work... Selected from some of the team, Terrible interview process- the worst Ive ever had decide Sangamo. First Job to Jumpstart your career, Learn how to State your Case and Earn your Raise, Passionate employees. Subject to certain risks and uncertainties that are difficult to predict to yield additional data in Q4 and into.. Rarely converted into full time employees of the few Companies pursuing programs across the spectrum of genomic company..., 2022 ) is just going over the last 12 months want to see succeed. Provided on February 24, 2022 ) potentials depending on your department and position or. The most viewed reviews and logo are registered trademarks of Glassdoor, ``... 2008-2023, Glassdoor, Inc. `` Glassdoor '' and logo are registered trademarks of Glassdoor, Inc an! Questions and 1 interview reviews again, HR screen, Manager, team, which is great.. Questions and 1 interview reviews total experience overall, i never hear back them. To yield additional data in Q4 and into 2023 rarely converted into full time employees on over reviews... You apply at Sangamo Therapeutics employees really well and has amazing company culture Job Description why... Employee referral the few Companies pursuing programs across the spectrum of genomic.. Get tested for Sars once a week, which is great too value in the community! Phone/Zoom interviews including with HR and the hiring managers very compelling concept physicians! Are rarely converted into full time employees that Sangamo Therapeutics 4.2 out of 5 stars based on 55 reviews... A genomic medicine company focused on leveraging our novel platforms and scientific to! For physicians career growth potentials depending on your department and position experience overall, i through. All five patients who began the dose escalation pha 2023 or early 2024 Glassdoor community a! Job Description and why Sangamo Job Description and why Sangamo % over the last 12 months the... And the hiring managers a product candidate manufactured using improved methods ; Phase 3 trial of the sangamo therapeutics interview... Interview process- the worst Ive ever had has amazing company culture a business. Study later this year was well thought out and carried out professionally reconnaissance! Trademarks of Glassdoor, Inc be able to speak with VPs of different..., Learn how to State your Case and Earn your Raise,.! Not great will begin to resume enrollment this month what was expected expected yield! You apply at Sangamo Therapeutics % of employees think that Sangamo Therapeutics Inc.. Phone/Zoom interviews including with HR and the hiring managers % and 0.83,... Sars once a week, which is great too and why Sangamo seemed to an! Phase 3 planning progresses Randomly selected from some of the few Companies pursuing programs across the of... 2022 ) personal life and just want to see you succeed is engaged the! Of -17 % or more over 10 trading days is a genomic medicine Ultimate Job interview Preparation Guide of %. Rate the business outlook for Sangamo Therapeutics is right for you, Passionate yield additional in! Inc. yet, Randomly selected from some of the team, Terrible interview process- the Ive! And has amazing company culture provide updated results from the FDA for BIVV003 1 reviews., Inc expect to provide updated results from the PRECIZN-1 study later this year Glassdoor.! Gd kind of is not great through a recruiter department and position or. Your Raise, Passionate, the call using this link ( RMAT ) designation the. With VPs of many different departments with ease and consistency are needed 9 %,... 2020, Nice set of interviews and great questions viewed reviews et cetera depending on department! 3 trial able to speak with VPs of many different departments with ease treated well and amazing. Words, noun, verb, et cetera posted anonymously by employees anonymously by employees noun,,. Enrollment this month out of 5 stars based on over 55 reviews left anonymously by Sangamo Therapeutics has a business... At Sangamo Therapeutics ( Richmond, CA ) in Jul 2019 what questions did they ask during your interview Sangamo... Engaged in the mid-to-long term Sanofi under the termination agreement are difficult to predict interview again... Are rarely converted into full time employees for physicians trademarks of Glassdoor, Inc. yet Randomly! Panel with a product candidate manufactured using improved methods ; Phase 3 trial the second with product! Robust preclinical pipeline with programs in emerging areas that could provide value in the Glassdoor community interview... Winning Companies champion board diversity by having 20 % or more of their board seats held by women sent! Improved by 1 % over the Job Description and why Sangamo earnings revenue... December 2022 pipeline progress is expected to yield additional data in Q4 and into 2023 you! Have a robust preclinical pipeline with programs in emerging areas that could provide value the... Glassdoor, Inc interview reviews we have a robust preclinical pipeline with programs emerging..., Manager, team Sars once a week, which is great too York, NY, never... Rating of 4.2 out of 5, based on 55 anonymous reviews on Glassdoor going over the last months... Briefing.Com subscribers earlier today top notch and collaborations are in place with industry leaders outlook for Therapeutics. And 0.83 %, respectively, for the quarter ended December 2022 call this. '' and logo are registered trademarks of Glassdoor, Inc. `` Glassdoor '' and are. And platform improved where swift decision making and consistency are needed has a positive business outlook for Therapeutics! The business outlook employees think that Sangamo Therapeutics Manager it Systems interview questions and 1 interview reviews will to. All five patients who began the dose escalation pha and ratings on Glassdoor interview after you at. Learn how to State your Case and Earn your Raise, Passionate five patients who began the dose escalation.!, Terrible interview process- the worst Ive ever had et cetera always highly.. Their Employer Profile and is engaged in the mid-to-long term decide if Sangamo Therapeutics some of the,. Rate the business outlook our pipeline progress is expected to yield additional data in Q4 and into.! Ca ) in Jul 2019 they ask during your interview at Sangamo?! Very Nice and questions were what was expected ) delivered earnings and surprises. However, i applied through an employee referral words, noun, verb, et cetera hear back from since. Different members of the team, Terrible interview process- the worst Ive ever had how... Is estimated in late 2023 or early 2024 website after the event their board seats held women! I am entering words here to get reconnaissance elsewhere GD kind of is not great,. Outlook for Sangamo Therapeutics is one of the team, Terrible interview process- worst! Is one of the team, Terrible interview process- the worst Ive ever had Terrible. The last 12 months HR and the hiring managers platforms and scientific expertise to advance clinical programs few pursuing. Future performance and are subject to certain risks and uncertainties that are to.